secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001140361-25-042598
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

European Commission approves BRINSUPRI as first treatment for NCFB in EU
------------------------------------------------------------------------

- EC approved BRINSUPRI (brensocatib 25 mg) for NCFB patients 12+ years with ≥2 exacerbations in prior 12 months.
- First and only approved treatment for non-cystic fibrosis bronchiectasis in the EU; reviewed under accelerated assessment.
- Phase 3 ASPEN study showed 19.4% reduction in annual exacerbation rate vs placebo; key secondary endpoints met.
- Approval follows positive CHMP opinion on 16 Oct 2025; Insmed plans EU access starting early 2026.
- Applications also under review in UK (MHRA) and Japan (PMDA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125042598/0001140361-25-042598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125042598/ef20059077_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-042598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer